The review article by Weir et al. (Nov. 10 issue)1 on acute oxygen-sensing mechanisms omits one of the most important of the mechanisms: the angiotensin-converting-enzyme (ACE) molecule. ACE is enriched in the pulmonary circulation, where it appears to function not only as a mechanosensor2 but also as a reduction-oxidation (redox) sensor.3 A central role for ACE in ventilation-perfusion matching would explain its involvement in lung pathology.4,5 ACE inhibition or angiotensin II blockade may be effective for treating acute and chronic lung diseases, including the acute respiratory distress syndrome, high-altitude pulmonary edema, viral pneumonia, bronchiolitis obliterans, pulmonary fibrosis, lung cancer, and chronic obstructive pulmonary disease.
Dr. Nauseef points out that the phagocytic NADPH oxidase in the plasma membrane releases reactive oxygen species on the outside of the cell. NADPH oxidase and its homologues may also release reactive oxygen species from intracellular granules, from the endoplasmic reticulum, and into intracellular phagocytic vacuoles.1,2 In the setting of hypoxic pulmonary vasoconstriction, these mechanisms are speculative, and if NADPH oxidase is involved, it seems more likely that hydrogen peroxide would diffuse back into the smooth-muscle cell across the plasma membrane. We have previously shown that NADPH oxidase, containing the gp91 phox subunit, is involved in normoxic generation of reactive oxygen species in mouse lungs.3 However, hypoxic pulmonary vasoconstriction persists when this source of reactive oxygen species is removed, suggesting that it is not essential for initiating that condition. Our work and that of others would favor the mitochondria as a source of signaling reactive oxygen species, at least in the pulmonary arteries.
The oxygen-sensitive factor HIF-1 may play a role in the body's response to inflammation and infection, as suggested by Dr. Eltzschig and colleagues. Although the many actions of HIF-1 are fascinating, they fall outside the scope of our review, which was limited to acute oxygen sensing. It is clear that the chronic response of the pulmonary vasculature to hypoxia does involve HIF activation. Rats that are heterozygous for HIF-1 manifest less chronic hypoxic pulmonary hypertension and have less right ventricular hypertrophy.4
Repeated periods of hypoxia have been associated with an increased incidence of dementia. Chronic hypoxia increases the formation of beta-amyloid peptides, and these in turn increase the expression of L-type calcium channels.5 As stated by Dr. Khan, the loss of calcium homeostasis may cause neurotoxicity and be involved in the pathophysiology of Alzheimer's disease.
Dr. Moskowitz asks whether ACE may play a part in oxygen sensing. Although ACE is active in the pulmonary circulation, we are unaware of rigorous data indicating that it is involved in hypoxic pulmonary vasoconstriction or in oxygen sensing in general. Angiotensin II, in common with many other vasoconstrictors, will enhance hypoxic pulmonary vasoconstriction, but this action is probably distinct from the mechanism of sensing. To date, few data in animals or humans have suggested that ACE inhibitors are beneficial in pulmonary hypertension. Any effect on the pulmonary circulation may be offset by the tendency to cause systemic vasodilation, which can cause hypotension and syncope in patients with pulmonary hypertension.
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